MLN2480 + irinotecan

MLN2480 + irinotecan is an experimental **combination therapy** evaluated for the treatment of advanced solid tumors. MLN2480 (also known as TAK-580) is a brain-penetrant, type II **RAF dimer inhibitor** targeting both monomeric and dimeric forms of BRAF, including oncogenic BRAF variants and fusions. It inhibits the RAF/MEK/ERK signaling pathway, crucial in the proliferation of many cancers, and has demonstrated effective brain penetration and pathway inhibition in preclinical models. Irinotecan is a standard chemotherapeutic agent that functions as a **topoisomerase I inhibitor**, blocking DNA replication in cancer cells and leading to apoptosis. The combination was dosed as MLN2480 taken orally and irinotecan intravenously. Initial development was focused on relapsed/refractory solid malignancies, testing safety, tolerability, and pharmacokinetics[1][2][3][4].